| Literature DB >> 22850543 |
Yejin Mok1, Soyoung Won, Heejin Kimm, Chungmo Nam, Heechoul Ohrr, Sun Ha Jee.
Abstract
BACKGROUND: Physical activity decreases deaths from cardiovascular disease and other causes; however, it is unclear whether physical activity is associated with cancer incidence and death in Asian populations.Entities:
Mesh:
Year: 2012 PMID: 22850543 PMCID: PMC3798560 DOI: 10.2188/jea.je20110110
Source DB: PubMed Journal: J Epidemiol ISSN: 0917-5040 Impact factor: 3.211
Baseline characteristics of study subjects according to MET-min/week (n = 59 636): The Severance Cohort Study, 1994–2004
| MET-min/week | ||||
| 0 | 3.5–1000 | >1000 | ||
| mean ± SD | mean ± SD | mean ± SD | ||
| Age (years) | 45.6 ± 10.6 | 47.2 ± 10.0 | 49.4 ± 10.0 | <0.0001 |
| Body mass index (kg/m2) | 24.1 ± 3.0 | 24.3 ± 2.7 | 24.5 ± 2.6 | <0.0001 |
| Systolic blood pressure (mm Hg) | 124.0 ± 18.2 | 124.3 ± 18.1 | 125.9 ± 18.9 | <0.0001 |
| Diastolic blood pressure (mm Hg) | 73.3 ± 12.0 | 73.0 ± 12.2 | 72.5 ± 12.1 | <0.0001 |
| Total cholesterol (mg/dL) | 196.4 ± 35.5 | 197.7 ± 34.2 | 198.6 ± 34.0 | <0.0001 |
| HDL cholesterol (mg/dL) | 46.2 ± 11.6 | 46.7 ± 11.5 | 47.7 ± 11.6 | <0.0001 |
| Triglyceride (mg/dL) | 170.1 ± 118.4 | 164.4 ± 109.0 | 160.6 ± 114.1 | <0.0001 |
| Fasting glucose (mg/dL) | 98.2 ± 26.5 | 98.5 ± 24.0 | 99.6 ± 25.1 | 0.0017 |
| GGT (IU/L) | 47.8 ± 68.3 | 40.1 ± 43.0 | 40.4 ± 42.3 | <0.0001 |
| AST (IU/L) | 23.9 ± 23.7 | 22.1 ± 11.6 | 22.1 ± 10.8 | <0.0001 |
| ALT (IU/L) | 30.0 ± 31.3 | 27.0 ± 21.6 | 25.5 ± 17.8 | <0.0001 |
| % | % | % | ||
| Smoking status | ||||
| Ex-smoker | 24.3 | 34.0 | 40.3 | |
| Current smoker | 56.4 | 42.5 | 39.5 | <0.0001 |
| Alcohol intake (yes) | 81.3 | 86.4 | 85.7 | <0.0001 |
| Hypertension (yes) | 24.5 | 26.0 | 29.0 | <0.0001 |
| Diabetes (yes) | 6.8 | 8.0 | 9.4 | <0.0001 |
| mean ± SD | mean ± SD | mean ± SD | ||
| Age (years) | 47.4 ± 10.8 | 48.3 ± 10.2 | 47.5 ± 9.2 | 0.0398 |
| Body mass index (kg/m2) | 23.5 ± 3.3 | 23.4 ± 3.0 | 23.6 ± 2.8 | 0.7922 |
| Systolic blood pressure (mm Hg) | 121.8 ± 21.0 | 121.1 ± 20.4 | 120.9 ± 19.5 | 0.0042 |
| Diastolic blood pressure (mm Hg) | 72.8 ± 12.0 | 71.5 ± 11.7 | 70.7 ± 11.7 | <0.0001 |
| Total cholesterol (mg/dL) | 195.5 ± 37.9 | 197.6 ± 36.8 | 195.9 ± 36.0 | 0.0931 |
| HDL cholesterol (mg/dL) | 52.9 ± 12.8 | 54.8 ± 13.2 | 56.3 ± 13.6 | <0.0001 |
| Triglyceride (mg/dL) | 125.8 ± 83.0 | 120.8 ± 81.0 | 113.8 ± 74.1 | <0.0001 |
| Fasting glucose (mg/dL) | 94.4 ± 22.9 | 93.0 ± 18.6 | 92.8 ± 19.7 | <0.0001 |
| GGT (IU/L) | 19.5 ± 27.1 | 18.2 ± 18.5 | 17.8 ± 16.4 | <0.0001 |
| AST (IU/L) | 19.7 ± 17.0 | 19.1 ± 10.5 | 19.1 ± 8.9 | 0.0086 |
| ALT (IU/L) | 18.5 ± 22.0 | 17.8 ± 18.9 | 17.3 ± 12.7 | 0.0002 |
| % | % | % | ||
| Smoking status | ||||
| Ex-smoker | 2.3 | 2.6 | 2.4 | |
| Current smoker | 6.0 | 4.1 | 4.5 | <0.0001 |
| Alcohol intake (yes) | 27.4 | 27.7 | 30.8 | 0.0001 |
| Hypertension (yes) | 25.5 | 24.5 | 22.7 | 0.0002 |
| Diabetes (yes) | 4.9 | 5.3 | 4.6 | 0.6578 |
MET: metabolic equivalent of task; SD: standard deviation; HDL: high-density lipoprotein; GGT: γ-glutamyl transferase; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
Figure. Regression β-coefficients of DBP, TC, HDL, and ALT according to MET-week/min. DBP: diastolic blood pressure; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; ALT: alanine aminotransferase; MET: metabolic equivalent of task.
Hazard ratios (95% CI) of cancer incidence, all-cause death, cancer death, and noncancer death by MET-min/week in mena
| MET-min/week | ≥3.5 vs 0 | ||||
| 0 | 3.5–1000 | >1000 | |||
| ( | ( | ( | |||
| Cases | 1308 | 364 | 340 | ||
| Rateb | 9.3 | 8.9 | 8.9 | ||
| Model 1 | 1.0 | 0.92 (0.81–1.04) | 0.89 (0.79–1.01) | 0.0465 | 0.90 (0.82–1.00) |
| Model 2 | 1.0 | 1.00 (0.84–1.13) | 0.98 (0.84–1.13) | 0.0030 | 0.99 (0.88–1.11) |
| Cases | 1083 | 219 | 214 | ||
| Rateb | 8.2 | 5.6 | 6.8 | ||
| Model 1 | 1.0 | 0.70 (0.60–0.81) | 0.66 (0.56–0.76) | 0.0013 | 0.68 (0.60–0.76) |
| Model 2 | 1.0 | 0.73 (0.62–0.87) | 0.66 (0.55–0.79) | 0.0081 | 0.70 (0.61–0.79) |
| Cases | 539 | 99 | 122 | ||
| Rateb | 3.9 | 2.7 | 3.3 | ||
| Model 1 | 1.0 | 0.66 (0.53–0.81) | 0.79 (0.64–0.96) | 0.1818 | 0.72 (0.62–0.85) |
| Model 2 | 1.0 | 0.72 (0.57–0.92) | 0.78 (0.62–0.98) | 0.4211 | 0.75 (0.63–0.90) |
| Cases | 544 | 120 | 92 | ||
| Rateb | 4.3 | 2.9 | 3.5 | ||
| Model 1 | 1.0 | 0.74 (0.60–0.91) | 0.52 (0.41–0.66) | 0.0016 | 0.63 (0.53–0.75) |
| Model 2 | 1.0 | 0.75 (0.59–0.95) | 0.54 (0.41–0.70) | 0.0036 | 0.64 (0.53–0.78) |
aAdjusted for age, smoking status, alcohol intake, body mass index, hypertension, total cholesterol, and diabetes.
bAge-adjusted rate (per 100 000 person years).
Model 1: Without exclusion of early cases (those occurring within 3 years of the starting point).
Model 2: After exclusion of early cases (those occurring within 3 years of the starting point).
Hazard ratios (95% CI) of cancer incidence, all-cause death, cancer death, and noncancer death by MET-min/week in womena
| MET-min/week | ≥3.5 vs 0 | ||||
| 0 | 3.5–1000 | >1000 | |||
| ( | ( | ( | |||
| Cases | 1139 | 211 | 193 | ||
| Rateb | 6.7 | 6.7 | 6.7 | ||
| Model 1 | 1.0 | 0.93 (0.79–1.10) | 1.02 (0.86–1.20) | 0.5831 | 0.97 (0.86–1.10) |
| Model 2 | 1.0 | 0.94 (0.77–1.13) | 0.99 (0.81–1.19) | 0.3085 | 0.96 (0.83–1.11) |
| Cases | 630 | 81 | 66 | ||
| Rateb | 5.0 | 3.2 | 4.4 | ||
| Model 1 | 1.0 | 0.60 (0.46–0.77) | 0.71 (0.54–0.93) | <0.0001 | 0.65 (0.53–0.79) |
| Model 2 | 1.0 | 0.59 (0.44–0.79) | 0.78 (0.58–1.04) | <0.0001 | 0.67 (0.54–0.83) |
| Cases | 235 | 27 | 38 | ||
| Rateb | 1.6 | 1.1 | 1.5 | ||
| Model 1 | 1.0 | 0.62 (0.41–0.92) | 1.07 (0.76–1.52) | 0.1892 | 0.82 (0.62–1.08) |
| Model 2 | 1.0 | 0.62 (0.40–0.97) | 1.17 (0.80–1.69) | 0.3829 | 0.86 (0.64–1.17) |
| Cases | 395 | 54 | 28 | ||
| Rateb | 3.4 | 2.1 | 2.9 | ||
| Model 1 | 1.0 | 0.58 (0.41–0.82) | 0.44 (0.28–0.69) | <0.0001 | 0.52 (0.39–0.69) |
| Model 2 | 1.0 | 0.56 (0.38–0.84) | 0.47 (0.29–0.78) | <0.0001 | 0.52 (0.38–0.72) |
aAdjusted for age, smoking status, alcohol intake, body mass index, hypertension, total cholesterol, and diabetes.
bAge-adjusted rate (per 100 000 person years).
Model 1: Without exclusion of early cases (those occurring within 3 years of the starting point).
Model 2: After exclusion of early cases (those occurring within 3 years of the starting point).